Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 963037, 8 pages
http://dx.doi.org/10.1155/2009/963037
Research Article

A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma

Laboratory of Immuno-Oncology and Tumor Immunotherapy, Immunology Program, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, Canada J1H 5N4

Received 8 August 2009; Revised 21 December 2009; Accepted 29 December 2009

Academic Editor: Susan Chang

Copyright © 2009 Marie-Denise Poirier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. El Andaloussi, Y. U. Han, and M. S. Lesniak, “Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors,” Journal of Neurosurgery, vol. 105, no. 3, pp. 430–437, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. A. Rosenberg, P. Spiess, and R. Lafreniere, “A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes,” Science, vol. 233, no. 4770, pp. 1318–1321, 1986. View at Google Scholar · View at Scopus
  3. T. L. Whiteside and G. Parmiani, “Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use,” Cancer Immunology Immunotherapy, vol. 39, no. 1, pp. 15–21, 1994. View at Google Scholar · View at Scopus
  4. A. El Andaloussi and M. S. Lesniak, “An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme,” Neuro-Oncology, vol. 8, no. 3, pp. 234–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Read, V. Malmstrom, and F. Powrie, “Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation,” Journal of Experimental Medicine, vol. 192, no. 2, pp. 295–302, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Shimizu, S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi, “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunology, vol. 3, no. 2, pp. 135–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, “The B7 family revisited,” Annual Review of Immunology, vol. 23, pp. 515–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Valzasina, C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P. Colombo, “Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR,” Blood, vol. 105, no. 7, pp. 2845–2851, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Zheng, B. Wang, and A. Chen, “The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells,” Journal of Immunology, vol. 173, no. 4, pp. 2428–2434, 2004. View at Google Scholar · View at Scopus
  10. J. D. Fontenot, J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. Y. Rudensky, “Regulatory T cell lineage specification by the forkhead transcription factor Foxp3,” Immunity, vol. 22, no. 3, pp. 329–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Ermann, P. Hoffmann, M. Edinger et al., “Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD,” Blood, vol. 105, no. 5, pp. 2220–2226, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Ochando, C. Homma, Y. Yang et al., “Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts,” Nature Immunology, vol. 7, no. 6, pp. 652–662, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Adu, P. Cockwell, N. J. Ives, J. Shaw, and K. Wheatley, “Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials,” British Medical Journal, vol. 326, no. 7393, pp. 789–791, 2003. View at Google Scholar · View at Scopus
  15. E. M. Shevach, “Regulatory T cells in autoimmmunity,” Annual Review of Immunology, vol. 18, pp. 423–449, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. L. Mobley and M. O. Dailey, “Regulation of adhesion molecule expression by CD8 T cells in vivo. I: differential regulation of gp90MEL-14 (LECAM-1), Pgp-1, LFA-1, and VLA-4 alpha during the differentiation of cytotoxic T lymphocytes induced by allografts,” Journal of Immunology, vol. 148, no. 8, pp. 2348–2356, 1992. View at Google Scholar · View at Scopus
  17. P. Yu, Y. Lee, W. Liu et al., “Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors,” Journal of Experimental Medicine, vol. 201, no. 5, pp. 779–791, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. Jacob, Y.-C. M. Kong, C. Meroueh et al., “Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells,” Cancer Research, vol. 67, no. 14, pp. 7020–7027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Von Boehmer, “Mechanisms of suppression by suppressor T cells,” Nature Immunology, vol. 6, no. 4, pp. 338–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. El Andaloussi and M. S. Lesniak, “CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas,” Journal of Neuro-Oncology, vol. 83, no. 2, pp. 145–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. O. M. Grauer, S. Nierkens, E. Bennink et al., “CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglionia immune responses in vivo,” International Journal of Cancer, vol. 121, no. 1, pp. 95–105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. P. E. Fecci, A. E. Sweeney, P. M. Grossi et al., “Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells,” Clinical Cancer Research, vol. 12, no. 14, pp. 4294–4305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Zelenay and J. Demengeot, “Comment on “cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells”,” Journal of Immunology, vol. 177, no. 4, pp. 2036–2037, 2006, author reply 2037-2038. View at Google Scholar · View at Scopus
  24. L. A. Stephens and S. M. Anderton, “Comment on “cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells”,” Journal of Immunology, vol. 177, no. 4, pp. 2036–2037, 2006, author reply 2037-2038. View at Google Scholar · View at Scopus
  25. M. Feuerer, P. Beckhove, N. Garbi et al., “Bone marrow as a priming site for T-cell responses to blood-borne antigen,” Nature Medicine, vol. 9, no. 9, pp. 1151–1157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. L. L. Cavanagh, R. Bonasio, I. B. Mazo et al., “Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells,” Nature Immunology, vol. 6, no. 10, pp. 1029–1037, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. A. El Andaloussi, Y. Han, and M. S. Lesniak, “Progression of intracranial glioma disrupts thymic homeostasis and induces T-cell apoptosis in vivo,” Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1807–1816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Peng, Y. Laouar, M. O. Li, E. A. Green, and R. A. Flavell, “TGF-β regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4572–4577, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. Townsend and J. P. Allison, “Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells,” Science, vol. 259, no. 5093, pp. 368–370, 1993. View at Google Scholar · View at Scopus
  30. A. F. Ochsenbein, S. Sierro, B. Odermatt et al., “Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction,” Nature, vol. 411, no. 6841, pp. 1058–1064, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Melero, W. W. Shuford, S. A. Newby et al., “Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors,” Nature Medicine, vol. 3, no. 6, pp. 682–685, 1997. View at Publisher · View at Google Scholar · View at Scopus